Mineralys Therapeutics (Nasdaq: MLYS) will report first-quarter 2026 financial results for the period ended March 31, 2026, after market close on Wednesday, May 6, 2026. A conference call and live webcast will begin at 4:30 p.m. ET with domestic and international dial-in access and a webcast link on the investor site.
Loading...
Loading translation...
Positive
None.
Negative
None.
News Market Reaction – MLYS
+4.26%
+4.26%Session close to close
In the Apr 30 session, MLYS gained 4.26%, reflecting a moderate positive market reaction.
This announcement schedules Mineralys Therapeutics’ Q1 2026 results for May 6, 2026 with a conferenc...
Analysis
This announcement schedules Mineralys Therapeutics’ Q1 2026 results for May 6, 2026 with a conference call at 4:30 p.m. ET, providing investors a clear timeline for the next financial update. A similar earnings-date notice on Mar 09, 2026 preceded a modestly positive move of 2.44%. Ahead of the call, context includes recent regulatory progress for lorundrostat and ongoing insider trading activity disclosed in multiple recent SEC filings.
Key Figures
Q1 2026 period end:March 31, 2026Earnings release date:Wednesday, May 6, 2026Conference call time:4:30 p.m. ET+3 more
6 metrics
Q1 2026 period endMarch 31, 2026First quarter financial period referenced in the release
Announced Q4 and full-year 2025 results release and conference call timing.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Pattern Detected
For prior earnings-date announcements, the single tagged event showed a modest positive price reaction.
Recent Company History
Over recent months, Mineralys has combined clinical and regulatory milestones with routine corporate updates. A prior earnings-date notice on Mar 09, 2026 about reporting Q4 and full-year 2025 results and hosting a 4:30 p.m. ET call corresponded with a 2.44% gain over the next day. Today’s Q1 2026 earnings-date announcement fits that same pattern of scheduling communication without new financial figures or clinical data.
Key Terms
chronic kidney disease, ckd, obstructive sleep apnea, osa, +1 more
5 terms
chronic kidney diseasemedical
"comorbidities such as chronic kidney disease (CKD), obstructive sleep apnea"
Chronic kidney disease is a long-term, progressive loss of kidney function that reduces the organs’ ability to filter waste, control fluid levels and balance body salts. For investors, CKD matters because it creates sustained demand for tests, drugs, dialysis machines and transplants; advances in treatment or regulatory decisions can meaningfully change revenue prospects for companies—like a car that needs ongoing repairs, it creates predictable, long-term market needs.
ckdmedical
"comorbidities such as chronic kidney disease (CKD), obstructive sleep apnea"
Chronic kidney disease (CKD) is a long-term condition where the kidneys gradually lose their ability to filter waste and fluids from the blood, like household filters that slowly clog and underperform over time. It matters to investors because CKD drives demand for drugs, medical devices, diagnostics and dialysis services, influences healthcare spending and reimbursement decisions, and creates regulatory or clinical-trial risks and market opportunities across the healthcare sector.
obstructive sleep apneamedical
"comorbidities such as chronic kidney disease (CKD), obstructive sleep apnea (OSA)"
Obstructive sleep apnea is a common medical condition where the throat repeatedly narrows or closes during sleep, causing short pauses in breathing, drops in blood oxygen and fragmented rest. It matters to investors because it creates ongoing demand for medical devices, diagnostics, treatments and sleep-monitoring services, and it can affect population health, workforce productivity and healthcare spending—like a recurring leak in a system that requires continual repair and monitoring.
osamedical
"comorbidities such as chronic kidney disease (CKD), obstructive sleep apnea (OSA)"
Obstructive sleep apnea (OSA) is a common sleep disorder where the upper airway repeatedly narrows or collapses during sleep, causing brief breathing stoppages that fragment rest and raise daytime tiredness and health risks. For investors, OSA creates sustained demand for diagnostic tests, therapy devices, drugs and monitoring services, so changes in clinical data, approvals, or reimbursement can materially affect revenue prospects for companies in the sleep-health sector.
aldosteronemedical
"other diseases driven by dysregulated aldosterone, announced it will report its"
Aldosterone is a hormone made by small glands above the kidneys that helps the body hold on to salt and water and release potassium, functioning like a household thermostat that adjusts fluid levels. It matters to investors because drugs or tests that change or measure aldosterone can alter treatment of high blood pressure, heart failure and kidney disease, affecting sales, trial outcomes and regulatory decisions in related healthcare markets.
RADNOR, Pa., April 29, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, announced it will report its financial results from the first quarter ended March 31, 2026, after the financial markets close on Wednesday, May 6, 2026.
A live webcast of the conference call may also be found on the “News & Events” page in the Investor Relations section of the Mineralys Therapeutics website.
About Mineralys Therapeutics Mineralys Therapeutics is a biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as CKD, OSA and other diseases driven by dysregulated aldosterone. Its initial product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor. Mineralys is based in Radnor, Pennsylvania, and was founded by Catalys Pacific. For more information, please visit https://mineralystx.com. Follow Mineralys on LinkedIn, Twitter and Bluesky.
When will Mineralys Therapeutics (MLYS) report Q1 2026 results and what time is the conference call?
Mineralys will report Q1 2026 results after market close on May 6, 2026, with a 4:30 p.m. ET call. According to Mineralys Therapeutics, the company will present results for the quarter ended March 31, 2026 and host a simultaneous live webcast for investors.
How can investors join the Mineralys Therapeutics (MLYS) conference call on May 6, 2026?
Investors can join by dialing the domestic number 1-877-704-4453 or the international number 1-201-389-0920. According to Mineralys Therapeutics, participants should use Conference ID 13759844 and may also access the live webcast via the company's investor "News & Events" page.
Where will the Mineralys Therapeutics (MLYS) earnings webcast be available for the May 6, 2026 call?
The webcast will be available on the company's Investor Relations "News & Events" page. According to Mineralys Therapeutics, the live webcast link will stream the conference call beginning at 4:30 p.m. ET and remain accessible for investors following the event.
What period do the Mineralys Therapeutics (MLYS) Q1 2026 results cover?
The results cover the quarter ended March 31, 2026. According to Mineralys Therapeutics, the company will release financial results for that period after market close on May 6, 2026 and discuss them on the 4:30 p.m. ET conference call and webcast.
What is the conference ID for the Mineralys Therapeutics (MLYS) May 6, 2026 call?
The conference ID is 13759844 for the May 6, 2026 call at 4:30 p.m. ET. According to Mineralys Therapeutics, callers should use that ID when dialing the domestic or international numbers and can also listen via the live webcast on the investor site.
